Myelofibrosis Pipeline Outlook Report 2025: Key 35+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight's, "Myelofibrosis Pipeline Insights 2025" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight's comprehensive Myelofibrosis Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Myelofibrosis Pipeline Outlook Report [https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Myelofibrosis Pipeline Report

* In August 2025, Icahn School of Medicine at Mount Sinai announced a phase II study to assess the efficacy, safety, and tolerability of Reparixin in patients with DIPSS intermediate-2, or high-risk primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF) after prior treatment, and those who are ineligible or refuse treatment, with a Janus kinase inhibitor (JAKi). 26 patients will be enrolled. Eligible patients will receive oral reparixin three times daily on a 4-week cycle for a core study period of 6 cycles (24 weeks). After cycle 6, patients may continue receiving reparixin once daily on a 4-week cycle if at least stable disease (SD) is met by IWG-MRT criteria until loss of response, disease progression, unacceptable toxicity, patient/physician withdrawal, or termination of study by sponsor.
* DelveInsight's Myelofibrosis pipeline report depicts a robust space with 35+ active players working to develop 40+ pipeline therapies for Myelofibrosis treatment.
* The leading Myelofibrosis Companies such as Geron Corporation, Merck, Telios Pharma Inc., Ryvu Therapeutics SA, Taiga Biotechnologies, Inc., Morphic Therapeutic, iOnctura, Pharmaxis, Nippon Shinyaku, Active Biotech, Incyte Corporation, Sumitomo Pharma America, Inc., and others.
* Promising Myelofibrosis Therapies such as Momelotinib, Luspatercept, Bomedemstat, Pacritinib, RVU120, Ruxolitinib , and others.

Discover how the Myelofibrosis treatment paradigm is evolving. Access DelveInsight's in-depth Myelofibrosis Pipeline Analysis for a closer look at promising breakthroughs @ Myelofibrosis Clinical Trials and Studies [https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Myelofibrosis Emerging Drugs Profile

* Imetelstat: Geron Corporation

Imetelstat sodium (imetelstat) is a small oligonucleotide composed of a nucleic acid and a lipid moiety. The proprietary nucleic acid backbone provides resistance to degradation, thus conferring improved stability in plasma and tissues, as well as significantly improved binding affinity to its target. The lipid group enhances cell permeability, which results in increased potency and improved pharmacokinetic and pharmacodynamic properties.

* Bomedemstat: Merck

Bomedemstat is an irreversible inhibitor of lysine-specific demethylase 1 (LSD1), an enzyme critical for regulating the proliferation of hematopoietic stem cells and the maturation of progenitors. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Myelofibrosis.

* TL-895: Telios Pharma, Inc.

It is an orally bioavailable inhibitor of tyrosine kinase, with potential anti-inflammatory and antineoplastic activities. Upon oral administration, tyrosine kinase inhibitor TL-895 targets, binds to, and inhibits tyrosine kinase. This may result in the inhibition of tumor angiogenesis and cell proliferation, and the inhibition of immune-mediated inflammatory processes. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Myelofibrosis.

* RVU120: Ryvu Therapeutics SA

RVU120 is a selective, first-in-class dual CDK8/19 kinase inhibitor developed by Ryvu Therapeutics. RVU120's mechanism of action (MoA) involves targeting CDK8/19 kinases. Specifically, translational data confirm the proposed MoA in a molecularly-defined subset of patients with DNMT3A and NPM1 mutations. Currently, the drug is in the Phase II stage of development to treat Myelofibrosis.

* TBX-2400: Taiga Biotechnologies, Inc.

TBX-2400 is an allogeneic stem cell therapy developed by Taiga Biotechnologies that aims to improve the rate of engraftment and reconstitution of the immune system for patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Currently, the drug is in the Phase I stage of development to treat Myelofibrosis.

The Myelofibrosis Pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Myelofibrosis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myelofibrosis Treatment.
* Myelofibrosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Myelofibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myelofibrosis market.

Get a detailed analysis of the latest innovations in the Myelofibrosis pipeline. Explore DelveInsight's expert-driven report today! @ Myelofibrosis Unmet Needs [https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Myelofibrosis Companies

Geron Corporation, Merck, Telios Pharma Inc., Ryvu Therapeutics SA, Taiga Biotechnologies, Inc., Morphic Therapeutic, iOnctura, Pharmaxis, Nippon Shinyaku, Active Biotech, Incyte Corporation, Sumitomo Pharma America, Inc., and others.

Myelofibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Myelofibrosis Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Download DelveInsight's latest report to gain strategic insights into upcoming Myelofibrosis Therapies and key Developments @ Myelofibrosis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Myelofibrosis Pipeline Report

* Coverage- Global
* Myelofibrosis Companies- Geron Corporation, Merck, Telios Pharma Inc., Ryvu Therapeutics SA, Taiga Biotechnologies, Inc., Morphic Therapeutic, iOnctura, Pharmaxis, Nippon Shinyaku, Active Biotech, Incyte Corporation, Sumitomo Pharma America, Inc., and others.
* Myelofibrosis Therapies- Momelotinib, Luspatercept, Bomedemstat, Pacritinib, RVU120, Ruxolitinib, and others.
* Myelofibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Myelofibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Myelofibrosis drug development? Find out in DelveInsight's exclusive Myelofibrosis Pipeline Report-access it now! @ Myelofibrosis Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Myelofibrosis: Overview
* Myelofibrosis Pipeline Therapeutics
* Myelofibrosis Therapeutic Assessment
* Myelofibrosis - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Imetelstat: Geron Corporation
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* RVU120: Ryvu Therapeutics SA
* Drug profiles in the detailed report.....
* TBX-2400: Taiga Biotechnologies, Inc.
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Myelofibrosis Key Companies
* Myelofibrosis Key Products
* Myelofibrosis- Unmet Needs
* Myelofibrosis- Market Drivers and Barriers
* Myelofibrosis- Future Perspectives and Conclusion
* Myelofibrosis Analyst Views
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=myelofibrosis-pipeline-outlook-report-2025-key-35-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/myelofibrosis-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.